AUPH - Aurinia Pharmaceuticals Inc.
| Previous Close | 15.00 |
| Open | 15.00 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 14.26 - 16.07 |
| 52 Week Range | 3.52 - 17.48 |
| Volume | 14,114,639 |
| Avg. Volume | 2,270,125 |
| Market Cap | 1.453B |
| Beta (3Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- Barrons.com
A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know
Another biotech company, (ACAD) (ACAD), also saw its stock jump 14%. There is sure to be more big biotech news coming up. It makes sense for GM to pair up with LG Chem (051910.Korea), rather than go it alone.
- Barrons.com
Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data
Drug-trial news sent shares of Aurinia Pharmaceuticals soaring Thursday morning and Sage Pharmaceuticals tumbling.
- Zacks
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up
Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.
- Benzinga
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- MarketWatch
Aurinia Pharmaceuticals surges more than 110%, after positive trial for lupus-related drug
Aurinia Pharmaceuticals Inc. stock rampaged in the extended session, rising more than 110% after the company announced positive efficacy and safety results from a Phase 3 trial for a drug that treats a common complication of lupus, an autoimmune disease. The complication known as lupus nephritis is a frequent complication of the disease commonly known as lupus. "This extraordinary pivotal data confirms voclosporin's ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care," Chief Medical Officer Neil Solomons said in a statement. "This data represents a significant advance for people living with LN, which can lead to irreversible kidney damage, eventual kidney failure and death." The company's drug is called voclosporin, and Aurinia said it expects that if it achieves regulatory approval then patent protection for the drug will be extended in the U.S. and Europe, among other markets, until 2027. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia and trades on the Toronto Stock Exchange and the Nasdaq. Prior to Wednesday's after-hours stock move, Aurinia stock had gained 23% this year, as the S&P 500 index also rose 23%.
- Business Wire
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal AURORA Phase 3 trial of voclosporin, in combination with mycophenolate ("MMF") and low-dose corticosteroids, in the treatment of lupus nephritis ("LN").
- Business Wire
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced that an abstract has been accepted for presentation at the Keystone Symposia Conference on Islet Biology: From Gene to Cell to Micro-Organ in Santa Fe, New Mexico from January 27-31, 2020. The abstract will be presented by Dr. James D. Johnson, Professor of Medicine in the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia (UBC).
- Zacks
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
- Simply Wall St.
Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit
Aurinia Pharmaceuticals Inc.'s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company...
- Zacks
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -10.53% and 360.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
- Conference call and webcast to be hosted today at 4:30pm EDT –
- Business Wire
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the appointment of Ms. Jill Leversage to its Board of Directors and the resignation of Dr. Hyeuk Joon Lee. Ms. Leversage began her finance career at Burns Fry Ltd., and has held senior level positions at BMO Financial Group, RBC Capital Markets, and TD Securities. Ms. Leversage is a Fellow of the Institute of Chartered Professional Accountants of British Columbia and also a Chartered Business Valuator (ret.) of the Canadian Institute of Chartered Business Valuators.
- Insider Monkey
Were Hedge Funds Right About Souring On Aurinia Pharmaceuticals Inc (AUPH)?
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
- Zacks
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Options Traders Expect Huge Moves in Aurinia (AUPH) Stock
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
- Business Wire
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the completion of a FDA-requested clinical drug-drug interaction (“DDI”) study in patients with lupus that investigated the potential effect of voclosporin on blood levels of mycophenolate acid (“MPA”), the active metabolite of mycophenolate mofetil (“MMF”). MMF, also known as CellCept®, is considered by treating physicians to be part of the current standard of care for lupus nephritis (“LN”) in the United States.
- Business Wire
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
Aurinia Pharmaceuticals Inc. today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes.
- Business Wire
Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the initiation of patient dosing in the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (“VOS”) for the potential treatment of dry eye syndrome (“DES”).
- Zacks
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Business Wire
Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today reported that the last patient study visit has occurred in the AURORA Phase 3 lupus nephritis (“LN”) study. Efficacy and safety results from AURORA remain on track to be reported by the end of the fourth quarter 2019.
- Simply Wall St.
Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market?
If you own shares in Aurinia Pharmaceuticals Inc. (TSE:AUP) then it's worth thinking about how it contributes to the...
- TipRanks
3 Biotech Stocks That Could Triple in 2020
2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is down more than six percentage points, against near 16% rise for the S&P 500.But not all biotechs are created equal -- and not all biotech stocks will remain as cheap as they are today. Utilizing the Stock Screener at TipRanks to seek out strong-buy-rated stocks with incredible profit potential, we've come up with a trio of small cap biotechs with a chance to triple their share price (or more) in the coming year. Let's take a closer look:Aurinia Pharmaceuticals (AUPH)Based out of Victoria, British Columbia, Aurinia Pharmaceuticals is a clinical-stage biotech developing a drug called voclosporin, which it hopes will prove useful in treating lupus nephritis (LN), an autoimmune disease affecting the kidneys, focal segmental glomerulosclerosis (another kidney disease) -- or if not those, then maybe dry eye syndrome.If that sounds to you like Aurinia hasn't quite decided "what it wants to be when it grows up" ... well, we kind of wonder about that, too. Still, the company has $131 million in the bank and minimal debt. With a cash burn rate of only $51 million, Aurinia has the better part of three years to figure itself out and get its drug to market to accomplish something.Just recently, Oppenheimer analyst Justin Kim initiated coverage of Aurinia stock with an outperform rating on the theory that voclosporin "could become the first therapeutic approved for treatment of LN." Kim thinks the drug has a 60% chance of proving successful for that purpose, and the stock could be worth $10 a share if that's the only indication the drug is approved for. If voclosporin proves effective in treating the other two diseases, the stock could be worth even more. (To watch Kim's track record, click here)"Considering the near-term readout of the pivotal Phase 3 LN study, we anticipate shares could re-rate following a positive primary outcome in 4Q19. In addition to an initial pipeline opportunity in FSGS and a maturing late-stage program in dry eye syndrome, we are positive on the stock’s setup into 2020," Kim opined.All in all, Wall Street likes the risk/reward factor at play here, as TipRanks showcases a strong buy consensus rooting for Aurinia's success. In fact, the consensus of analysts following Aurinia is that this stock could triple in value over the next 12 months, rising from $5 and approaching $17 per share. (See AUPH's price targets and analyst ratings on TipRanks)TherapeuticsMD (TXMD)TherapeuticsMD is a somewhat different story. On the one hand, it's a higher-price stock with nearly twice Aurinia's market capitalization, and a weaker balance sheet -- $183 million in cash, and $198 million in debt -- with a much higher burn rate of $152 million per annum. On the other hand, TherapeuticsMD has several products under development, including two formulations of topical progesterone cream.TherapeuticsMD even has products on the market, including estrogen insert "Imvexxy," for the treatment of menopause-related dyspareunia (sales of which are accelerating year over year), "Bijuva" for the treatment of menopause-related "hot flashes," and soon, "Annovera," a contraceptive insert.Cowen analyst Ken Cacciatore commented that Imvexxy sales were growing "in line with our expectations," that the company is "making progress" with Bijuva, and that it's "optimistic" about Annovera's launch early next year. On Imvexxy in particular, Cacciatore highlighted the 41% year over year growth in paid prescriptions written, and noted that patients using the drug are refilling their prescriptions at nearly twice the usual rate for products in this category.Despite the apparently weak balance sheet, Cacciatore believes"the company remains sufficiently capitalized to reach profitability" by the second half of 2021.Oppenheimer Jay Olson echoes Cacciatore's tone, noting, "We believe TXMD offers a unique portfolio of women's health products that currently remains undervalued with attractive market opportunities. Based on our hypothetical SOTP analysis, we value Imvexxy at $2/share, Bijuva at $5/share, and Annovera at $1/share."Street analysts agree, TherapeuticsMD stock could triple off of today's sub-$4 share price and approach $12 per share in the next 12 months. (See TXMD's price targets and analyst ratings on TipRanks)Dynavax Technologies (DVAX) Last but not least \-- well actually, it is least in terms of market capitalization at just $305 million -- we come to Dynavax Technologies, which sells the hepatitis B vaccine Heplisav-B, and has a phase 2 clinical trial candidate for cancer immunotherapy (DV281) and a phase 2a candidate for asthma treatment as well (AZD1419) -- along with a phase 1 clinical trial product for the treatment of non-small cell lung cancer (DV281).Like TherapeuticsMD , Dynavax is a company in perilous financial state, with a cash-poor balance sheet ($140 million cash, $213 million debt) and a rapid cash burn rate -- $158 million per annum. Regardless, Cowen analyst Phil Nadeau has high hopes for this one, noting that Heplisav "has been shown to be more effective and more convenient than the other currently marketed HBV vaccines in a number of Phase III trials," which suggests Dynavax may be safe from competition in this space for some time.Indeed, already Nadeau says Heplisav is gaining market share, and predicts the drug could capture as much as $365 million of the $500 million-plus market for hepatitis B vaccines by 2024 -- a better than 70% market share.As a result, Nadeau rates DVAX an Outperform with a $20 price target, which implies a whopping 440% upside from current levels. (To watch Nadeau's track record, click here)"With Heplisav's label favorable, we expect it to become the market-leading HBV vaccine over time. Our consultants think that the other monovalent HBV vaccines are good, but not ideal. Although quite safe and generally effective, our consultants think they have two shortfalls: First, they are not perfectly effective, particularly in “hyporesponders” – people over the age of 40 and people with a number of diseases – for whom they provide suboptimal protection. Second, the marketed HBV vaccines require 3 (or more) doses over six months, which reduces compliance and hence protection," Nadeau noted.Analysts following the stock believe Dynavax shares to be significantly undervalued at today's sub-$4 share price, and predict Dynavax could go to $16 next year. More than a mere triple -- this stock could quadruple in 2020. (See DVAX's price targets and analyst ratings on TipRanks)
